Author | Joseph Jurcic, MD | OncLive

Author | Joseph Jurcic, MD


Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

June 11, 2015


Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Dr. Jurcic on the Next Steps for Radioimmunotherapy

June 30, 2014


Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.